A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
Phase 2
Completed
- Conditions
- Overactive Bladder
- Registration Number
- NCT00337090
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1108
Inclusion Criteria
- Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months
Exclusion Criteria
- Pregnant and breastfeeding women
- Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
3 Sites
🇷🇺St Petersburg, Russian Federation
2 Sites
🇸🇪Stockholm, Sweden
7 Sites
🇷🇺Moscow, Russian Federation